

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 403 173
A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90306260.2

(22) Date of filing: 08.06.90

(51) Int. Cl.5: C12N 15/76, C12N 15/90,
C12P 19/62, //(C12N15/76,
C12R1:465)

(30) Priority: 12.06.89 US 364959

(43) Date of publication of application:
19.12.90 Bulletin 90/51

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI NL SE

(71) Applicant: ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis Indiana 46285(US)

(72) Inventor: Cox, Karen Leigh
Box 204 Painted Hills
Martinsville, Indiana 46151(US)
Inventor: Richardson, Mark Alan
4906 North Central Avenue
Indianapolis, Indiana 46205(US)
Inventor: Kuhstoss, Stuart Allen
5339 North Park Avenue
Indianapolis, Indiana 46220(US)
Inventor: Schoner, Brigitte Elisabeth
R.R. 2, Box 30 F
Monrovia, Indiana 4657(US)
Inventor: Rao, Ramachandra Nagaraja
9110 Misty Lake Circle
Indianapolis, Indiana 46260(US)
Inventor: Seno, Eugene Thomas
5109 East 72nd Court
Indianapolis, Indiana 46250(US)

(74) Representative: Hudson, Christopher Mark et
al
Erl Wood Manor
Windlesham Surrey GU20 6PH(GB)

(54) Novel use of the site-specific integrating function of phage OC31.

(57) The present invention provides a method for transforming an actinomycete with an integrating vector which has the advantages of high transformation rates into a broad host range, site-specific integration, and stable maintenance without antibiotic selection. Also provided are methods for the increased production of antibiotics and for the production of hybrid antibiotics.

EP 0 403 173 A2

NOVEL USE OF THE SITE-SPECIFIC INTEGRATING FUNCTION OF PHAGE ØC31

The in vivo amplification of genes coding for proteins involved in the biosynthesis of antibiotics can serve to increase production of that antibiotic. In actinomycetes, the usual route to this amplification has been via autonomously replicating plasmids. For reviews of Streptomyces cloning systems, see Hopwood et al., in 153 Methods in Enzymology 116 (1987) and Hopwood et al., in 9 The Bacteria 159 (1986). The present invention provides methods for increasing a given gene dosage and for adding heterologous genes that lead to the formation of new products such as hybrid antibiotics. The procedures of the present invention have many advantages over methods involving autonomously replicating plasmids.

Plasmids comprising the site-specific integrating function of phage ØC31 can be used to permanently integrate copies of the gene of choice into the chromosome of many different hosts. The vectors can transform these hosts at a very high efficiency. Because some of the vectors do not have actinomycete origins of replication, the plasmids cannot exist as autonomously replicating vectors in actinomycete hosts. The plasmids only exist in their integrated form in these hosts. The integrated form is extremely stable which allows the gene copies to be maintained without antibiotic selective pressure. The result is highly beneficial in terms of cost, efficiency, and stability of the fermentation process.

The integrating vectors can be used to integrate genes which increase the yield of known products or generate novel products, such as hybrid antibiotics or other novel secondary metabolites. The vector can also be used to integrate antibiotic resistance genes into strains in order to carry out bioconversions with compounds to which the strain is normally sensitive. The resulting transformed hosts and methods of making the antibiotics are within the scope of the present invention.

The present invention represents a significant advance in the introduction and maintenance of cloned genes in the antibiotic producing streptomycetes and related organisms. The invention is based on the use of an ~2 kb fragment of actinophage ØC31 (Chater et al., Gene 19:21-32 (1982). A vector which comprises this fragment, plasmid pKC796, is available from the NRRL (Northern Regional Research Laboratories, Peoria, Illinois 61604) under the accession number B-18477 (date of deposit: April 4, 1989). The plasmid has been deposited in accordance with the terms of the Budapest Treaty. See Figure 1 for a restriction map of pKC796.

For purposes of the present invention as disclosed and claimed herein, the following terms are as defined below.

Antibiotic - a substance produced by a microorganism that, either naturally or with limited chemical modification, inhibits the growth of or kills another microorganism or eukaryotic cell.

Antibiotic Biosynthetic Gene - a DNA segment that encodes an enzymatic activity or encodes a product that regulates expression of an enzymatic activity that is necessary for an enzymatic reaction in the process of converting primary metabolites to antibiotic intermediates, which can also possess antibiotic activity, and then to antibiotics.

Antibiotic Biosynthetic Pathway - the set of antibiotic biosynthetic genes and biochemical reactions necessary for the process of converting primary metabolites to antibiotic intermediates and then to antibiotics.

Antibiotic-Producing Microorganism - any organism, including, but not limited to Actinoplanes, Actinomadura, Bacillus, Cephalosporium, Micromonospora, Penicillium, Nocardia, and Streptomyces, that either produces an antibiotic or contains genes that, if expressed, would produce an antibiotic.

Antibiotic Resistance-Confering Gene - a DNA segment that encodes an activity that confers resistance to an antibiotic.

AmR - the apramycin-resistant phenotype or gene conferring same.

ApR - the ampicillin-resistant phenotype or gene conferring same.

attP - the attachment site of phage ØC31 for integration into the host chromosome.

cos site - the lambda cohesive end sequence.

Host Cell - an organism, including the viable protoplast thereof, that can be transformed with a recombinant DNA cloning vector.

Hybrid Antibiotic - an antibiotic produced when a heterologous antibiotic-biosynthetic gene is introduced into an antibiotic producing microorganism, said antibiotic biosynthetic gene encoding an enzyme that is capable of modifying the antibiotic produced by the original host cell.

Integrating Vector - a vector which, when transformed into a host cell, does not autonomously replicate within the host cell but rather integrates into the host chromosome by recombination.

ori - as used in the Figures herein, an E. coli origin of replication.

Recombinant DNA Cloning Vector - any selectable and autonomously replicating or chromosomally

integrating agent, including but not limited to plasmids and phages, comprising a DNA molecule to which additional DNA can be or has been added.

rep - as used in the Figures herein, a Streptomyces plasmid origin of replication.

Restriction Fragment - any linear DNA generated by the action of one or more restriction enzymes.

5 Sensitive Host Cell - a host cell, including the viable protoplast thereof, that cannot grow in the presence of a given antibiotic without a DNA segment that confers resistance thereto.

Site-specific integration - the process of integration by a vector into the host chromosome that utilizes specific bacterial (attB) and plasmid or phage (attP) attachment sites and specific recombinational system (int) coded by plasmid or phage.

10 Transformant - a recipient host cell, including the viable protoplast thereof, that has undergone transformation.

Transformation - the introduction of DNA into a recipient host cell, including the viable protoplast thereof, and subsequent maintenance of said DNA that results in a change in the genotype of the recipient cell.

15 tsr - the thiostrepton-resistant phenotype or gene conferring same.

The restriction site and function maps presented in the Figures are approximate representations of the recombinant DNA vector discussed herein. The spacing of restriction sites on the map is proportional to the actual spacing of the restriction sites on the vector, but observed restriction site distances may vary somewhat from calculated map distances. The maps do not necessarily provide an exhaustive listing of all the cut sites of a given restriction enzyme; therefore, there may be more restriction sites of a given type on the vector than actually shown on the map.

Figure 1 - Restriction Site and Function Map of Plasmid pKC796.

Figure 2 - Restriction Site and Function Map of Plasmid pOJ171.

Figure 3 - Restriction Site and Function Map of Plasmid pOJ242.

25 Figure 4 - Restriction Site and Function Map of Plasmid pOJ243.

Figure 5 - Restriction Site and Function Map of Plasmid pHJL280.

Figure 6 - Restriction Site and Function Map of Plasmid pSKC50.

Figure 7 - Restriction Site and Function Map of Plasmid pSKC51.

30 The present invention provides plasmid vectors which comprise the site-specific integrating function of the actinomycete phage ØC31. The DNA sequence of this region, presented below, was unknown prior to the present invention. Only one strand of the sequence is shown, reading in the 5' → 3' direction.

35

40

45

50

55

1 CGTCCCGTAC AACGTCGCGC GTGAGCGGGT CGGTTCCGGT GAAGAGATAC
 51 AGGGTCATGG AACGCGCGCT ACAGCGCCGG AAAAACGGAA CCTGGGTCGT
 5 101 GCGCAAGAAT CCGCCGTTCG TGATCTTCGA TGAAGTCATG GGCGATTACT
 151 GCGCGCTGCC CCAGGACGAC GACGGCGAGC CGGTGACGCT CGAATGGCGT
 201 TCGCGGTCGG CGGCGTATGA CTGGCTCGCC CACTGCCTTC AGACGTGGCA
 251 GATGTGGGAG CGCACGGGGC GAGCCGCTGA CGTCCCGAAG GCGTGGCGCG
 10
 AatII
 301 GCTTCCCCGT GCCGGAGCAA TCGCCCTGGG TGGGTTACAC GACGCCCTC
 351 TATGGCCCGT ACTGACGGAC ACACCGAAGC CCCGGCGGCA ACCCTCAGCG
 15 401 GATGCCCCGG GGCTTCACGT TTTCCCAGGT CAGAAGCGGT TTTCGGGAGT
 451 AGTGCCCCAA CTGGGGTAAC CTTTGAGTTC TCTCAGTTGG GGGCGTAGGG
 501 TCGCCGACAT GACACAAGGG GTTGTGACCG GGGTGGACAC GTACGCGGGT
 20 551 GCTTACGACC GTCAGTCGCG CGAGCGCGAG AATTCGAGCG CAGCAAGCCC
 601 AGCGACACAG CGTAGCGCCA ACGAAGACAA GCGGGCCGAC CTTCAGCGCG
 651 AAGTCGAGCG CGACGGGGGC CGGTTTCAGGT TCGTCGGGCA TTTCAGCGAA
 701 GCGCCGGGCA CGTCGGCGTT CGGGACGGCG GAGCGCCCGG AGTTCGAACG
 25 751 CATCCTGAAC GAATGCCGCG CCGGGCGGCT CAACATGATC ATTGTCTATG
 801 ACGTGTGCGC CTTCTCGCGC CTGAAGGTCA TGGACGCGAT TCCGATTGTC
 851 TCGGAATTGC TCGCCCTGGG CGTGACGATT GTTTCCACTC AGGAAGGCGT
 30 901 CTTCCGGCAG GGAACGTCA TGGACCTGAT TCACCTGATT ATGCGGCTCG
 951 ACGCGTCGCA CAAAGAATCT TCGCTGAAGT CGGCGAAGAT TCTCGACACG
 1001 AAGAACCTTC AGCGCGAATT GGGCGGGTAC GTCGGCGGGA AGGCGCCTTA
 35 1051 CGGCTTCGAG CTTGTTTCGG AGACGAAGGA GATCACGCGC AACGGCCGAA
 1101 TGGTCAATGT CGTCATCAAC AAGCTTGCGC ACTCGACCAC TCCCCTTACC
 1151 GGACCCTTCG AGTTCGAGCC CGACGTAATC CGGTGGTGGT GGCGTGAGAT
 1201 CAAGACGCAC AAACACCTTC CCTTCAAGCC GGGCAGTCAA GCCGCCATTC
 40 1251 ACCCGGGCAG CATCACGGGG CTTTGTAAGC GCATGGACGC TGACGCCGTG
 1301 CCGACCCGGG GCGAGACGAT TGGGAAGAAG ACCGCTTCAA GCGCCTGGGA
 1351 CCCGGCAACC GTTATGCGAA TCCTTCGGGA CCCGCGTATT GCGGGCTTCG
 45 1401 CCGCTGAGGT GATCTACAAG AAGAAGCCGG ACGGCACGCC GACCACGAAG
 1451 ATTGAGGGTT ACCGCATTCA GCGCGACCCG ATCACGCTCC GGCCGGTCGA

50

55

5
10
15
20
25
30
35
40
45
50
55

1501 GCTTGATTGC GGACCGATCA TCGAGCCCGC TGAGTGGTAT GAGCTTCAGG
1551 CGTGGTTGGA CGGCAGGGGG CGCGGCAAGG GGCTTTCCCG GGGGCAAGCC
1601 ATTCTGTCCG CCATGGACAA GCTGTACTGC GAGTGTGGCG CCGTCATGAC
1651 TTCGAAGCGC GGGGAAGAAT CGATCAAGGA CTCTTACCGC TGCCGTCGCC
1701 GGAAGGTGGT CGACCCGTCC GCACCTGGGC AGCACGAAGG CACGTGCAAC
1751 GTCAGCATGG CGGCACTCGA CAAGTTCGTT GCGGAACGCA TCTTCAACAA
1801 GATCAGGCAC GCCGAAGGCG ACGAAGAGAC GTTGGCGCTT CTGTGGGAAG
1851 CCGCCCGACG CTTGCGCAAG CTCACTGAGG CGCCTGAGAA GAGCGGCGAA
1901 CGGGCGAACC TTGTGTGCGA GCGCGCCGAC GCCCTGAACG CCCTTGAAGA
1951 GCTGTACGAA GACCGCGCGG CAGGCGCGTA CGACGGACCC GTTGGCAGGA
2001 AGCACTTCCG GAAGCAACAG GCAGCGCTGA CGCTCCGGCA GCAAGGGGCG
2051 GAAGAGCGGC TTGCCGAACT TGAAGCCGCC GAAGCCCCGA AGCTTCCCCT
2101 TGACCAATGG TTCCCCGAAG ACGCCGACGC TGACCCGACC GGCCCTAAGT
2151 CGTGGTGGGG GCGCGCGTCA GTAGACGACA AGCGCGTGTT CGTCGGGCTC
2201 TTCGTAGACA AGATCGTTGT CACGAAGTCG ACTACGGGCA GGGGGCAGGG
2251 AACGCCCATC GAGAAGCGCG CTTGATCAC GTGGGCGAAG CCGCCGACCG
2301 ACGACGACGA AGACGACGCC CAGGACGGCA CGGAAGACGT AGCGGCGTAG
2351 CGAGACACCC GGGGAAGCCTG TTAGGCGCTG AGACGGGCGC ACAGCGGGCT
2401 TCCTGGGGCA GCGGGAAGGG TCGGCCGGTC CCCCGGTCGG CCCATTTCTC
2451 TTGTCTCGGT TTAGTTAGTT AGCCTAAGTA ACAGTGACTC CGTCACCACA
2501 GCACAGCGGG GCGAGCCGTT GACCTGGGGG AAGTGATGCT GTGACGGAAT
2551 GACTCGAAAC ACACATTCCT AATGACTTCT CATTGGGTAA TCCAGACTTC
2601 ACGTCCACTT CATCACAGCG TCACCCGGGC GCCCTTCGCT GTGACCCCGA
2651 ATCAGGTTGC CGACAACCTT CATATAGGTA GAGGGGTTTA CGCGCCACGC
2701 ATCAAGCACC GCTAAGGAAC GCGGTCGAGC GCTACCCACT CAGGCCGGTC
2751 ACTCCCCTGA TCTCTCCCAG GGTGAGCGA CCGGCGTTGC CTCCCTAGCT
2801 CAGTTCGGTT AGAGCGCCTG TTTCGTAATC AGGGGGTCGG CGGTTTCAAT
2851 CCGTCGGGGG GCTCAATGAG CGGATACACA ATCGCTTGGC TCGCATGGCT
2901 TGCCGCGTTC GGCATCATTG AGGGTCGAGC GCTCTTCAAT AAGAAGCCGG
2951 GCGACACGCT GAGCGAACAC GTCTGGTCAT GGTTCGCCAC GCAAAGCCGG
3001 AGTACAGGCA AGCCTTCGGG TTGGGTGCGT GCTCGACGCT TTGCGCTACT

3051 GGCCTTCATG GGTGGGCTCA CTGCCCACTT CATGACGGGC GGTGCTTCT
 3101 AGCXCTGCCG CGCCCAGCCT ACTCACGTGA GTAGGTAGGG GGGTGTGAC
 5 3151 GGATAGGGGG GTGTCCCCGG AAGGGGGGGG GGGGTGCCCT ATGCGTACCC
 3201 GGTGTCTCGA CTGTAGGGAC TGGGCTACTC ATGGTGGGCG CTGTGCTCAG
 3251 CACCACGCCA CCTATCAGGC ACAGCGCAGT GTGAAGAGCC ATGCGAAGCG
 3301 GCGTGCTGCT ATCGCCCGTG GGAACAACGC TCGGGCGAAG ATGCGTCGTG
 10 3351 CTATCCGTAA GGCAGTGGGC GCGCACTGTG CTACCTGCCT GGGTTGGTAC
 3401 C

15 wherein A is a deoxyadenyl residue, G is a deoxyguanyl residue, C is a deoxycytidyl residue, T is a thymidyl residue, and X is a deoxyadenyl, deoxycytidyl, deoxyguanyl or thymidyl residue.

The DNA sequence comprising all the elements of DNA required for site-specific integration is bounded by the AatII restriction site (underlined) beginning at position 279 and the underlined thymidyl nucleotide at position 2369 of the above sequence. Plasmids comprising this sequence transform actinomycetes at
 20 extremely high rates. The plasmids are superior to phage cloning vectors comprising this sequence (Suarez, J.E. and Chater, K.F., Nature 286:527-529 (1980)) in that there is less limitation on the amount of DNA which can be cloned into the plasmid. The cloning capacity of phage vectors is limited to the amount of DNA which can be packaged.

Those skilled in the art will readily recognize that the variety of vectors which can be created that
 25 comprise this fragment is virtually limitless. The only absolute requirement is that the plasmid comprise an origin of replication which functions in the host cell in which constructions are made, such as *E. coli* or *Bacillus*. No actinomycete origin of replication is required. In fact, a preferred plasmid comprising the ϕ C31 fragment comprises no actinomycete origin of replication. Other features, such as an antibiotic resistance gene, a multiple cloning site and *cos* site are useful but not required. A description of the generation and
 30 uses of cosmid shuttle vectors can be found in Rao et al., 1987, in *Methods in Enzymology*, 153:166-198 (R.Wu and L. Grossman, eds. Academic Press, NY). In short, any plasmid which comprises the ϕ C31 fragment and which does not direct the formation of phage plaques is within the scope of this invention.

A preferred embodiment of the present invention is plasmid pKC796 (see Figure 1). The plasmid has an
 35 *E. coli* origin of replication derived from the pUC plasmids (available from Bethesda Research Laboratories, Inc., P.O. Box 577, Gaithersburg, MD 20760) which facilitates plasmid construction. Because plasmid construction in *E. coli* is so simple and quick compared to constructions carried out in *Streptomyces*, it is advantageous that all the initial steps can be carried out in *E. coli*. Only the final product is then transformed into *Streptomyces* for use in antibiotic production.

The vector has no *Streptomyces* origin of replication, which is a great advantage in an integrating
 40 vector. Multiple origins of replication in a chromosome can lead to instability of the construction. Experiments have shown that transformation rates for vectors with a *Streptomyces* origin of replication and an integrating function are far lower than transformation rates for vectors with either function alone. This result may be due to the instability problem.

Plasmid pKC796 also comprises the attachment site (*attP*) of *Streptomyces* phage ϕ C31. Chater et al.,
 45 Gene 19: 21-32 (1982). The site is on an ~4 kb *Clal-KpnI* fragment derived from ϕ C31. The protein(s) recognizing the *attP* and *attB* site direct site-specific integration into the chromosome. Once integrated, the construction is extraordinarily stable with virtually no reversion to the natural state. The site-specific nature of the integration facilitates analysis of the integrants.

Plasmid pKC796 also comprises the apramycin resistance gene, which is conveniently selectable in
 50 both *E. coli* and *Streptomyces*. The apramycin selection during the transformation process in *Streptomyces* ensures that integration has occurred due to the fact that there is no *Streptomyces* origin of replication on the vector. The apramycin selection can then be removed without fear of loss of the desired phenotype, as the integrated DNA is stable.

The vector comprises a multiple cloning site within the *lac α* (β -galactosidase) gene. See Figure 4 for
 55 the available cloning sites. An *E. coli* transformant carrying the pKC796 plasmid with an insert is easily detected as a white colony (as opposed to blue) when grown on media containing Xgal (5-bromo-4-chloro-3-indolyl- β -D-galactoside) and IPTG (isopropyl- β -D-thiogalactoside).

One of the most important assets of the present invention is the vectors' ability to transform many

actinomycete strains at very high rates. The following table shows the results of some representative transformations with plasmid pKC796.

Table I

Strain	Approximate Transformation Frequency (per μg DNA)
<u>S. ambofaciens</u>	$\geq 10^6$
<u>S. griseofuscus</u>	$\geq 10^6$
<u>S. lividans</u>	$\geq 10^6$
<u>S. lipmanii</u>	$\geq 10^4$
<u>S. fradiae</u>	$\geq 10^3$
<u>S. thermotolerans</u>	$\geq 10^3$
<u>Amycolatopsis orientalis</u>	$\geq 10^2$

The following tables provide a non-exhaustive list of antibiotic-producing microorganisms to which the present invention may be applied. The invention, in some instances, may also be used to generate increased amounts of products or novel products other than antibiotics.

TABLE II

Aminocyclitol Antibiotic-Producing Organisms

	<u>Organism</u>	<u>Antibiotic</u>
5		
10	<u>Bacillus</u>	
	various species	various aminocyclitols
15	<u>Micromonospora</u>	
	various species	gentamycins
20	<u>Saccharopolyspora</u>	
	various species	various aminocyclitols
25	<u>Streptomyces</u>	
	<u>albogriseolus</u>	neomycins
	<u>albus</u> var. <u>metamycinus</u>	metamycin
	<u>aquacanus</u>	N-methyl hygromycin B
30	<u>atrofaciens</u>	hygromycins
	<u>bikiniensis</u>	streptomycin
	<u>bluensis</u> var. <u>bluensis</u>	bluensomycin
	<u>canus</u>	ribosyl paromamine
35	<u>catenulae</u>	catenulin
	<u>chrestomyceticus</u>	aminosidine
	<u>crystallinus</u>	hygromycin A
40	<u>erythrochromogenes</u>	
	var. <u>narutoensis</u>	streptomycin
	<u>euroidicus</u>	A16316-C
45	<u>fradiae</u>	hybrimycins and neomycins
	<u>fradiae</u> var. <u>italicus</u>	aminosidine

50

55

TABLE II (Continued)

	<u>Organism</u>	<u>Antibiotic</u>
5	<u>Streptomyces</u>	
	<u>galbus</u>	streptomycin
10	<u>griseus</u>	streptomycin
	<u>griseoflavus</u>	MA 1267
	<u>hofuensis</u>	seldomycin complex
15	<u>hygroscopicus</u>	hygromycins, leucanicidin, and hygrolidin
20	<u>hygroscopicus</u> forma	
	<u>glebosus</u>	glebomycin
	<u>hygroscopicus</u> var.	
	<u>limoneus</u>	validamycins
25	<u>hygroscopicus</u> var.	
	<u>sagamiensis</u>	spectinomycin
	<u>kanamyceticus</u>	kanamycin A and B
30	<u>kasugaensis</u>	kasugamycins
	<u>kasugaspinus</u>	kasugamycins
	<u>lavendulae</u>	neomycin
35	<u>lividus</u>	lividomycins
	<u>mashuensis</u>	streptomycin
	<u>microsporeus</u>	SF-767
40	<u>netropsis</u>	LL-AM31
	<u>noboritoensis</u>	hygromycins
	<u>olivaceus</u>	streptomycin
	<u>olivoreticuli</u> var.	
45	<u>cellulophilus</u>	destomycin A

50

55

TABLE II (Continued)

	<u>Organism</u>	<u>Antibiotic</u>
5		
	<u>poolensis</u>	streptomycin
	<u>rameus</u>	streptomycin
10	<u>ribosidificus</u>	SF733
	<u>rimofaciens</u>	destomycin A
	<u>rimosus</u> forma	
15	<u>paromomycinus</u>	paromomycins and catenulin
	<u>spectabilis</u>	spectinomycin
20	<u>tenebrarius</u>	tobramycin and apramycin
	<u>Streptoverticillium</u>	
25	<u>flavopersicus</u>	spectinomycin

TABLE III

30	Ansamycin Antibiotic-Producing Organisms	
	<u>Organism</u>	<u>Antibiotic</u>
35	<u>Micromonospora</u>	
	various species	various ansamycins
	<u>Nocardia</u>	
40	<u>mediterranei</u>	rifamycin
	<u>Streptomyces</u>	
45	<u>collinus</u>	ansatrienes and naphthomycins
	<u>diastochromogenes</u>	ansatrienes and naphthomycins
	<u>galbus</u> subsp. <u>griseosporus</u>	naphthomycin B
	<u>hygroscopicus</u>	herbimycin
	<u>hygroscopicus</u> var. <u>geldanus</u> var. <u>nova</u>	geldamycin
	<u>nigellus</u>	21-hydroxy-25-demethyl 25-methylthioprotostreptovaricin
	<u>rishiriensis</u>	mycotrienes
50	sp. E/784	actamycin and mycotrienes
	sp. E88	mycotrienes
	<u>spectabilis</u>	streptovaricins
	<u>tolypophorus</u>	tolypomycin

TABLE IV

Anthracycline and Quinone Antibiotic-Producing Organisms	
Organism	Antibiotic
<u>Streptomyces</u>	
<u>caespitosus</u>	mitomycins A, B, and C
<u>coelicolor</u>	actinorhodin
<u>coeruleorubidicus</u>	daunomycin
<u>cyaneus</u>	ditrisarubicin
<u>flavogriseus</u>	cyanocycline A
<u>galilaeus</u>	aclacinomycin A, auramycins, and sulfurmycins
<u>lusitanus</u>	naphthyridinomycin
<u>peuceticus</u>	daunomycin and adriamycin
<u>violochromogenes</u>	arugomycin

TABLE V β -Lactam Antibiotic-Producing Organisms

	<u>Organism</u>	<u>Antibiotic</u>
10	<u>Nocardia</u>	
	<u>lactamadurans</u>	cephamycin C
	<u>uniformis</u>	nocardicin
15	<u>Streptomyces</u>	
	<u>antibioticus</u>	clavulanic acid
20	<u>argenteolus</u>	asparenomycin A, MM 4550, and MM 13902
	<u>cattleya</u>	thienamycin
25	<u>chartreusis</u>	SF 1623 and cephamycin A and B
	<u>Streptomyces</u>	
30	<u>cinnamonensis</u>	cephamycin A and B
	<u>clavuligerus</u>	PA-32413-I, cephamycin C, A16886A, penicillins
35		cephalosporins, clavulanic acid, and other clavams
	<u>fimbriatus</u>	cephamycin A and B
	<u>flavovirens</u>	MM 4550 and MM 13902
40	<u>flavus</u>	MM 4550 and MM 13902
	<u>fulvoviridis</u>	MM 4550 and MM 13902
	<u>griseus</u>	cephamycin A and B and carpetimycin A and B
45	<u>halstedii</u>	cephamycin A and B

TABLE V (Continued)

	<u>Organism</u>	<u>Antibiotic</u>
5		
	<u>heteromorphus</u>	C2081X and
		cephamycin A and B
10	<u>hygroscopicus</u>	deacetoxycephalosporin C
	<u>lipmanii</u>	cephamycin, penicillin N,
		7-methoxycephalosporin C,
15		A16884, MM4550, MM13902
	<u>olivaceus</u>	epithienamycin F,
		MM 4550, and MM 13902
20	<u>panayensis</u>	C2081X and
		cephamycin A and B
	<u>rochei</u>	cephamycin A and B
	<u>sioyaensis</u>	MM 4550 and MM 13902
25	sp. OA-6129	OA-6129A
	sp. KC-6643	carpetimycin A
	<u>viridochromogenes</u>	cephamycin A and B
30	<u>wadayamensis</u>	WS-3442-D
35		
40		
45		
50		
55		

TABLE VI

5	Macrolide, Lincosamide, and Streptogramin Antibiotic-Producing Organisms	
10	<u>Organism</u>	<u>Antibiotic</u>
	<u>Micromonospora</u>	
	<u>rosaria</u>	rosaramicin
15	<u>Saccharopolyspora</u>	erythromycins
	<u>erythraea</u>	
	<u>Streptomyces</u>	
20	<u>albireticuli</u>	carbomycin
	<u>albogriseolus</u>	mikonomycin
	<u>albus</u>	albomycetin
	<u>albus</u> var.	
25	<u>coilmyceticus</u>	coleimycin
	<u>ambofaciens</u>	spiramycin and
		foromacidin D
30	<u>antibioticus</u>	oleandomycin
	<u>avermittilis</u>	avermectins
	<u>bikiniensis</u>	chalcomycin
	<u>bruneogriseus</u>	albocycline
35	<u>caelestis</u>	M188 and celesticetin
	<u>cinerochromogenes</u>	cineromycin B
	<u>cirratus</u>	cirramycin
40	<u>deltae</u>	deltamycins
	<u>djakartensis</u>	niddamycin
	<u>eurocidicus</u>	methymycin
45	<u>eurythermus</u>	angolamycin
	<u>fasciculus</u>	amaromycin

50

55

TABLE VI (Continued)

	<u>Organism</u>	<u>Antibiotic</u>
5	<u>Streptomyces</u>	
	<u>felleus</u>	argomycin and
10		picromycin
	<u>fimbriatus</u>	amaromycin
	<u>flavochromogenes</u>	amaromycin and
15		shincomycins
	<u>fradiae</u>	tylosin
	<u>fungicidicus</u>	NA-181
	<u>fungicidicus</u> var.	
20	<u>espinomyceticus</u>	espinomycins
	<u>furdicidicus</u>	mydecamycin
	<u>goshikiensis</u>	bandamycin
25	<u>griseofaciens</u>	PA133A and B
	<u>griseoflavus</u>	acumycin
	<u>griseofuscus</u>	bundlin
30	<u>griseolus</u>	griseomycin
	<u>griseospiralis</u>	relomycin
	<u>griseus</u>	borrelidin
	<u>griseus</u> ssp. <u>sulphurus</u>	bafilomycins
35	<u>halstedii</u>	carbomycin and leucanicidin
	<u>hygroscopicus</u>	tylosin
	<u>hygroscopicus</u> subsp.	
40	<u>aureolacrimosus</u>	milbemycins
	<u>kitastoensis</u>	leucomycin A ₃ and
		josamycin
45	<u>lavendulae</u>	aldgamycin
	<u>lincolnensis</u>	lincomycin

50

55

TABLE VI (Continued)

<u>Organism</u>	<u>Antibiotic</u>
<u>loidensis</u>	vernAMYcin A and B
<u>macrosporeus</u>	carbomycin
<u>maizeus</u>	ingramycin
<u>mycarofaciens</u>	acetyl-leukomycin, and espinomycin
<u>narbonensis</u>	josamycin and narbomycin
<u>narbonensis</u> var. <u>josamyceticus</u>	leucomycin A ₃ and josamycin
<u>olivochromogenes</u>	oleandomycin
<u>platensis</u>	platenomycin
<u>rimosus</u>	tylosin and neutramycin
<u>rochei</u>	lankacidin and borrelidin
<u>rochei</u> var. <u>volubilis</u>	T2636
<u>roseochromogenes</u>	albocycline
<u>roseocitreus</u>	albocycline
<u>spinichromogenes</u> var. <u>suragaoensis</u>	kujimycins
<u>tendae</u>	carbomycin
<u>thermotolerans</u>	carbomycin
<u>venezuelae</u>	methymycins
<u>violaceoniger</u>	lankacidins and lankamycin

TABLE VII

Miscellaneous Antibiotic-Producing Streptomyces		
Antibiotic Type	Streptomyces Species	Antibiotic
amino acid analogues cyclopentane ring-containing	sp.	cycloserine
	<u>coelicolor</u>	methylenomycin A
	<u>erythrochromogenes</u>	sarkomycin
	<u>kasugaensis</u>	aureothricin and thiolutin
nitro-containing polyenes	<u>violaceoruber</u>	methylenomycin A
	<u>venezuelae</u>	chloramphenicol
	<u>griseus</u>	candididin
	<u>nodosus</u>	amphotericin B
tetracyclines	<u>noursei</u>	nystatin
	<u>aureofaciens</u>	tetracycline, chlortetracycline, demethyltetracycline, and demethylchlortetracycline
	<u>rimosus</u>	oxytetracycline

TABLE VIII

Nucleoside Antibiotic-Producing Organisms	
Organism	Antibiotic
<u>Corynebacterium</u>	tunicamycin analogues
<u>michiganese</u> pv. <u>rathayi</u>	
<u>Nocardia</u>	
<u>candidus</u>	pyrazofurin
<u>Streptomyces</u>	
<u>antibioticus</u>	ara-A tunicamycin streptoviridans sinefungin tunicamycin
<u>chartreusis</u>	
<u>griseoflavus</u> var. <u>thuringiensis</u>	
<u>griseolus</u>	
<u>lysosuperificus</u>	

TABLE IX

Peptide Antibiotic-Producing Organisms	
Organism	Antibiotic
Actinoplanes	
<u>missouriensis</u> <u>teichomyceticus</u>	actaplanin teicoplanin
Nocardia	
<u>candidus</u> <u>lurida</u> <u>orientalis</u>	A-35512 and avoparcin ristocetin vancomycin
Streptomyces	
<u>antibioticus</u> <u>aureus</u> <u>canus</u> <u>eburosporeus</u> <u>haranomachiensis</u> <u>pristinaespiralis</u> <u>roseosporus</u> <u>toyocaensis</u> <u>virginiae</u>	actinomycin thiostrepton amphomycin LL-AM374 vancomycin pristinamycin lipopeptides, such as A21978C A47934 A41030

TABLE X

Polyether Antibiotic-Producing Organism

	<u>Organism</u>	<u>Antibiotic</u>
5		
10	<u>Actinomadura</u>	
	various species	various polyethers
	<u>oligosporus</u>	A80190
15		
	<u>Dactylosporangium</u>	
	various species	various polyethers
20		
	<u>Nocardia</u>	
	various species	various polyethers
25		
	<u>Streptomyces</u>	
	<u>albus</u>	A204, A28695A and B, and salinomycin
30	<u>aureofaciens</u>	narasin
	<u>bobili</u>	A80438
	<u>cacaoi</u> var.	
35	<u>asoensis</u>	lysocellin
	<u>chartreusis</u>	A23187
	<u>cinnamomensis</u>	monensin
	<u>conglobatus</u>	ionomycin
40	<u>eurocidicus</u> var.	
	<u>asterocidicus</u>	laidlomycin
	<u>flaveolus</u>	CP38936
45	<u>gallinaris</u>	RP 30504
	<u>griseus</u>	grisorixin

50

55

TABLE X continued

	<u>Organism</u>	<u>Antibiotic</u>
5		
	<u>hygroscopicus</u>	A218, emericid, DE3936,
		A120A, A28695A and B,
10		etheromycin, and
		dianemycin
	<u>lasaliensis</u>	lasalocid
15	<u>longwoodensis</u>	lysocellin
	<u>mutabilis</u>	S-11743a
	<u>pactum</u>	A80438
	<u>ribosidificus</u>	lonomycin
20	<u>violaceoniger</u>	nigericin
	<u>Streptoverticillium</u>	
25	various species	polyethers

If it is desired to create integrating vectors with features other than those of pKC796, the ØC31 fragment may be obtained from plasmid pKC796, deposited with the NRRL under accession number NRRL B-18477 by a combination of site-specific mutagenesis and restriction enzyme digestion. First, the plasmid may be site-specifically mutagenized in accordance with the method of Adelman et al., DNA 2:183-193 (1983), herein incorporated by reference, using the synthetic DNA fragment TGTTAGGCGCTGAGACGGGC-CCACAGCGGGCTTCCTGGGGC. Incorporating this fragment into the plasmid generates the restriction site Apal at the 3' end of the fragment. The fragment can then be isolated as a AatII-Apal restriction fragment. In some contexts it may be necessary to insert a promoter functional in actinomycetes at the AatII site. Such promoters are well-known to one skilled in the art. One skilled in the art may then insert the fragment as is into the plasmid of their choice or may adapt the ends with oligonucleotide linkers to insert the fragment at a desired restriction site. One skilled in the art will also recognize that a synthetic DNA fragment comprising any restriction site may be inserted into the plasmid using site-specific mutagenesis and the fragment subsequently isolated by digestion with that restriction enzyme.

The integrating vector of the present invention has great utility in many aspects of Streptomyces research and commercialization of Streptomyces fermentation products. Preferred uses are to integrate into the host chromosome extra copies of homologous genes or new copies of heterologous genes. The use is not limited to genes involved in antibiotic production or resistance. For example, genes involved in amino acid production could be integrated into an auxotrophic strain, which would enable the growth of the strain on media not supplemented with the particular amino acid. The salient feature of all such experiments is the subsequent maintenance of the genes without antibiotic selection.

One preferred use is exemplified by the integration of the carE gene of Streptomyces thermotolerans into the Streptomyces ambofaciens genome. The S. thermotolerans carE gene encodes a 4'-O-isovaleryl acylase which attaches the isovaleryl group of isovaleryl coenzyme A to a mycarose sugar residue of the macrolide antibiotic carbomycin. S. ambofaciens produces the macrolide antibiotic spiramycin and a variety of other spiramycin-related compounds that contain a mycarose residue with a 4'-O group. S. ambofaciens does not produce a 4'-O-isovaleryl acylase activity. The carE gene can be isolated from plasmid pOJ171, which can be obtained from the NRRL in E. coli K12 SF8 under the accession number NRRL B-18169 (date of deposit: February 6, 1987). A restriction site and function map of pOJ171 is presented in Figure 2.

The ~2.4 kb BamHI restriction fragment isolated from plasmid pOJ171 is inserted into BamHI-digested pKC796 (NRRL B-18477). The fragment can be inserted in both orientations, yielding plasmids pOJ242 and pOJ243 (see Figures 3 and 4, respectively). Both plasmids and the control vector pKC796 were transformed

into an *S. ambofaciens* strain such as NRRL 2420. Transformants were initially selected with the antibiotic apramycin. The plasmids necessarily integrate into the chromosome because no *Streptomyces* origins of replication are present on the vectors. Due to the stable integration, no subsequent maintenance with apramycin is required.

5 The presence of the *carE* gene in the *S. ambofaciens* chromosome causes the strain to produce isovaleryl spiramycin. The *S. ambofaciens* strains which have integrated the parent pKC796 vector continue to produce spiramycin. This method of producing isovaleryl spiramycin has two major advantages over methods involving the introduction of the *carE* gene on an autonomously replicating plasmid. First, the transformants can be grown without antibiotic selection, thus decreasing cost and increasing efficiency. The
10 second advantage is that the integrated transformants produce a greater amount of isovaleryl spiramycin than replicating plasmids carrying the same gene because replicating plasmids seem to depress antibiotic production. These advantages apply generally when the integrating vector is used with any gene and are not limited to situations where the *carE* gene is utilized.

The present invention thus provides a method for producing hybrid antibiotics, said method comprising
15 1) transforming a microorganism that produces an antibiotic with a plasmid vector comprising a DNA sequence which comprises the site-specific integrating functions of phage ØC31, said vector also comprising an antibiotic biosynthetic gene that codes for an enzyme or other gene product not previously expressed in said microorganism and that convert said antibiotic to an antibiotic not previously produced by said microorganism and

20 2) culturing said microorganism transformed with said vector under conditions suitable for producing the hybrid antibiotic.

Another preferred use of the integrating vector is to increase the production of an antibiotic by integrating the antibiotic biosynthetic gene(s) into the host chromosome via the vector. When production of the antibiotic is increased, it may also be valuable to integrate extra copies of the respective antibiotic
25 resistance gene(s) to avoid inhibition by the antibiotic. The production of many fermentation products such as tylosin, monensin, and narasin may be improved by this method.

Integration of cloned genes using the integrating vector has numerous advantages. Stable maintenance of cloned genes in streptomycete fermentations (which involve many cell generations) in the absence of a selective agent has been a significant problem which is overcome by the present invention. For example, in
30 tylosin production, stable maintenance of the cloned *tylF* gene enhances the conversion of macrocin to tylosin, providing larger quantities of tylosin. In addition to its stability, the integrative vector has a lesser inhibitory effect on antibiotic production than autonomous plasmids.

The use of the integrating vector to stably maintain cloned genes in order to increase antibiotic production is exemplified herein by using the vector and cloned tylosin biosynthetic genes to increase the
35 production of tylosin. See Examples 3-5.

Tylosin production strains such as *Streptomyces fradiae* T1405 accumulate the tylosin precursors demethylmacrocin and macrocin. Fermentation cultures of the strain with extra copies of the *tylE* and *tylF* genes integrated into the chromosome produce increased amounts of the *tylF*-encoded macrocin O-methyltransferase and *tylE*-encoded demethylmacrocin O-methyltransferase. The result is increased conver-
40 sion of demethylmacrocin to macrocin and macrocin to tylosin and thus, a greater yield of the desired end product tylosin. The *tylE* and *tylF* genes along with other tylosin biosynthetic genes were described in European Patent Publication Serial No. 0238323, published September 23, 1987.

The BamHI fragment comprising the *tylF* gene is derived from plasmid pHJL280 (available from the NRRL in *E. coli* K12 HB101 as NRRL B-18043 (date of deposit: February 18, 1986); see Figure 5). The
45 fragment is then inserted into BamHI-digested pKC796. The resulting plasmids (differing by the orientation of the inserted BamHI fragment) are called pSKC50 and pSKC51. When transformed into the *S. fradiae* production strain T1405, the integrated vector causes tylosin production to increase to 136% as compared to the production levels of the T1405 control of 100%. The stability of the transformants is demonstrated by the fact that virtually 100% of the colony forming units retain the apramycin resistance phenotype provided
50 by the vector after at least three passages in the absence of selection.

The ability to transform tylosin production strains is a feature not found with other site-specific integrative vectors tested. The experiment was attempted with two other *Streptomyces* site-specific integrating vectors lacking a *Streptomyces* origin of replication: pIJ4210, which is the *Streptomyces*
55 *coelicolor* minicircle cloned into the *E. coli* plasmid pBR325 (Lydiat et al., Mol. Gen. Genet. 203:79-88 (1986)) and plasmids (Kuhstoss et al., J. Bact. 171:16-23 (1989)) derived from the integrative *S. ambofaciens* plasmid pSAM2 (Pernodet et al., Mol. Gen. Genet. 198:35-41 (1984)). These plasmids could not be stably introduced into tylosin production strains of *S. fradiae*. Stable maintenance without antibiotic selection and very high transformation frequencies are the key advantages of an integrating plasmid vector

comprising the site-specific integration functions of ϕ C31.

The vector comprising cloned tylosin biosynthetic genes can also be used to increase the tylosin production of *S. fradiae* mutant strains such as GS15 (*tylF* mutant; NRRL 18058 (date of deposit: March 19, 1986)) and GS16 (*tylE* mutant; available from the American Type Culture Collection, Rockville, MD 20852 under accession number ATCC 31664). The aforementioned plasmids pSKC50 and pSKC51 comprise the *tylE* and *tylF* genes. These plasmids can be transformed into the *S. fradiae* mutant strains. The resulting transformants will produce increased yields of tylosin and be stably maintained.

Thus, an important aspect of the present invention is to provide a method for increasing the antibiotic-producing or antibiotic precursor-producing ability of an antibiotic-producing or antibiotic precursor-producing microorganism, said method comprising

1) transforming a microorganism that produces an antibiotic or an antibiotic precursor by means of an antibiotic biosynthetic pathway with an integrating vector comprising a DNA sequence which comprises the site-specific integrating functions of phage ϕ C31, said vector also comprising an antibiotic biosynthetic gene that codes for an enzyme or other gene product that is rate-limiting in said biosynthetic pathway; and

2) culturing said microorganism transformed with said vector under conditions suitable for cell growth, expression of said antibiotic biosynthetic gene, and production of antibiotic or an antibiotic precursor, subject to the limitation that said antibiotic biosynthetic gene selected in step (1) provides for an increase in the antibiotic-producing or antibiotic precursor-producing ability of said microorganism.

Illustrative tylosin biosynthetic genes that can be used for purposes of the present invention include, for example, the *tylA*, *tylB*, *tylC*, *tylD*, *tylE*, *tylF*, *tylG*, *tylH*, *tylI*, *tylJ*, *tylK*, *tylL*, and *tylM*, genes. Of this group, the *tylF* gene is preferred, because the macrocin O-methyltransferase enzyme encoded thereby appears to be rate-limiting in the tylosin biosynthetic pathway of most tylosin-producing strains. Macrocin accumulates to unacceptable levels under conditions of optimum fermentation of *Streptomyces fradiae* because of the rate-limiting step catalyzed by the *tylF* gene product. The *tylF* enzyme catalyzes the conversion of macrocin to tylosin. Overproduction of the *tylF* gene product, macrocin O-methyltransferase, results in the more efficient operation of the tylosin biosynthetic pathway as indicated by increased antibiotic yield and lower cost of fermentation.

Streptomyces strains can be cultured in a number of ways using any of several different media. Carbohydrate sources that are preferred in a culture media include, for example, molasses, glucose, dextran, and glycerol, and nitrogen sources include, for example, soy flour, amino acid mixtures, and peptones. Nutrient inorganic salts are also incorporated into the medium and include the customary salts capable of yielding sodium, potassium, ammonium, calcium, phosphate, chloride, sulfate, and like ions. As is necessary for the growth and development of other microorganisms, essential trace elements are also added. Such trace elements are commonly supplied as impurities incidental to the addition of other constituents of the medium. *Streptomyces* strains are grown under aerobic culture conditions over a relatively wide pH range of about 6 to 8 at temperatures ranging from about 25° to 37° C. At temperatures of about 34-37° C, antibiotic production may cease.

The following examples further illustrate and describe the invention disclosed herein. The invention is not limited in scope by reason of any of the following Examples; sources of reagents or equipment are provided merely for convenience and in no way limit the invention. Both an explanation of and the actual procedures for constructing the invention are described where appropriate.

Example 1

Isolation of Plasmid pKC796

Plasmid pKC796 (Figure 1) can be obtained from the Northern Regional Research Center (NRRL), Peoria, IL 61604, in *E. coli* K12 DH5 α under the accession number NRRL B-18477. The lyophilis of *E. coli* K12 DH5 α /pKC796 were plated onto L-agar plates (10 g of tryptone, 10 g of NaCl, 5 g of yeast extract, and 15 g of agar per liter) containing 100 μ g/ml apramycin to obtain a single colony isolate of the strain. This colony was used to inoculate about 500 ml of L broth (L agar without agar) containing 100 μ g/ml apramycin, and the resulting culture was incubated at 30° C with aeration until the cells reached stationary phase.

The cells were centrifuged at 8000 rpm for 10 minutes. After the supernatant was decanted, the cells

were resuspended in 7 ml of 25% sucrose, 50 mM Tris•HCl, pH 8.0. Freshly prepared lysozyme (0.25 ml of a 5 mg/ml solution) was added to the solution, along with 0.4 ml of 0.5 M EDTA (pH 8), and 0.05 ml of 5 mg/ml RNase A. The mixture was incubated for 15 minutes at 37° C. To this 0.75 ml of Triton lytic mix (150 mM Tris•HCl, pH 8.0, 3% Triton X-100®, 200 mM EDTA) was added, mixed, and incubated for 15 minutes on ice. If lysis was not complete, it was further incubated for about 5 minutes at 37° C. The mixture was centrifuged at 20,000 rpm for 40 minutes. The supernatant was removed and retained. A CsCl gradient (density of 1.55) was made by adding 28.65 g of CsCl to 31.2 ml of DNA solution. The gradient solution was mixed to dissolve and transferred to large ultracentrifuge tubes. The tubes were filled with ~0.6 ml of ethidium bromide (10 mg/ml), sealed and mixed.

The gradient was established by centrifugation at 49,000 rpm for 18 hours. The lower band of plasmid DNA as visualized with long-wave UV light was collected. The ethidium bromide was removed by extracting 4 to 5 times with isoamyl alcohol. The DNA solution was dialyzed against 2 liters of TE buffer (10 mM Tris•HCl, pH 8.0, 1 mM EDTA) and after 2 hours was replaced with fresh TE. The dialyzed solution was extracted twice with phenol and twice with chloroform:isoamyl alcohol (24:1). The DNA was ethanol precipitated by adding one-tenth volume of 3 M sodium acetate and 3 volumes of ethanol. The DNA was collected by centrifugation for 10 minutes at 10,000 rpm, washed with 70% ethanol and then 100% ethanol, dried and dissolved in about 250 µl of sterile TE. The concentration and purity was estimated by measuring optical density at 260 and 280 nm. A restriction site and function map of pKC796 is presented in Figure 1 of the accompanying drawings.

Example 2

Construction of Plasmid pOJ242 and pOJ243

A. Isolation of Plasmid pOJ171

Plasmid pOJ171 can be obtained from the NRRL in *E. coli* K12 SF8 under the accession number NRRL B-18169. Plasmid pOJ171 is a source of the *carE* gene. The lyophils of *E. coli* K12 SF8/pOJ171 are plated onto L-agar plates containing 100 µg/ml apramycin to obtain a single colony isolate of the strain. This colony is used to inoculate about 500 ml of L broth containing 100 µg/ml apramycin and the resulting culture is incubated at 37° C with aeration until the cells reach stationary phase.

Plasmid DNA is obtained from the cells to use in construction of plasmids pOJ242 and pOJ243 in substantial accordance with the procedure set forth in Example 1, above. A restriction site and function map of plasmid pOJ171 is presented in Figure 2 of the accompanying drawings.

B. Final Construction of Plasmids pOJ242 and pOJ243

Plasmids pOJ242 and pOJ243 are vectors that comprise the *carE* gene. The plasmids can be constructed in the following manner. About 10 µg (10 µl) of plasmid pKC796 DNA is added to 2 µl of 10X BamHI buffer (60 mM Tris-HCl, pH 7.9; 1.5 M NaCl; and 60 mM MgCl₂), 6 µl of H₂O, and 2 µl (~40 units; unit definitions herein correspond to those of New England Biolabs (NEB), 32 Tozer Road, Beverly, MA 01915-9990, unless otherwise indicated) of restriction enzyme BamHI. The resulting reaction is incubated at 37° C for two hours. The BamHI-digested plasmid pKC796 DNA is extracted and then collected by adjusting the sodium acetate (NaOAc) concentration of the reaction mixture to 0.30 M, adding 2.5 volumes of ethanol, chilling the reaction mixture to -70° C, and centrifuging to pellet the precipitated DNA. The pellet of BamHI-digested plasmid pKC796 DNA is resuspended in 10 µl of TE buffer.

About 20 µg of plasmid pOJ171 in 10 µl of TE buffer are added to 75 µl of H₂O, 10 µl of 10X BamHI buffer (60 M Tris-HCl, pH 7.9; 1.5 M NaCl; and 60 mM MgCl₂), and 5 µl (~100 units) of restriction enzyme BamHI. The resulting reaction is incubated at 37° C for 2 hours. The reaction mixture is extracted and the DNA collected as described above. The DNA pellet is dissolved in ~10 µl of TE buffer. The DNA is electrophoresed on a low-melting agarose gel (BioRad, 2200 Wright Ave., Richmond, GA, 94804) in substantial accordance with the procedure in Maniatis et al., 1982, Molecular Cloning (Cold Spring Harbor

Laboratory).

The gel is prepared by heating 100 ml of 0.8% low-melting agarose in 1X TAE buffer (40 mM Tris-acetate, pH 7.5, 2 mM EDTA). The mixture is cooled to 37 °C and the gel is run at 4 °C. Two µl of loading-buffer (0.25% bromophenol blue, 0.25% xylene cyanol, 30% glycerol in H₂O) are added to the DNA sample.

5 The sample is loaded onto the gel. The gel is run at 100 V at 4 °C until the bromophenol blue dye nears the bottom of the gel. The gel is stained with 0.5 µg/ml ethidium bromide and the desired ~2.4 kb BamHI band is detected by long wave UV fluorescence and excised. To the gel piece is added 5 volumes of 20 mM Tris-HCl (pH 8.0) and 1 mM EDTA. The gel is melted at 65 °C for 5 minutes. The sample is extracted with an equal volume of phenol. The sample is centrifuged, the aqueous layer recovered and reextracted, and

10 the DNA collected as described above. The DNA pellet is dissolved in 10 µl of TE buffer and contains ~0.5 µg of the desired ~2.4 kb BamHI restriction fragment of plasmid pOJ171.

The BamHI-digested plasmid pKC796 DNA (1 µl) is added to 10 µl (~0.5 µg) of the BamHI restriction fragment from pOJ171, 2 µl of 10X ligase buffer (660 mM Tris-HCl, pH 8.0; 66 mM MgCl₂; 10 mM dithiothreitol (DTT); and 10 mM ATP), and 6 µl of H₂O. About 1 µl (~100 units) of T4 DNA ligase is added

15 to the solution of DNA, and the resulting reaction is incubated at 15 °C overnight (~16 hours). The ligated DNA contains the desired plasmids pOJ242 and pOJ243 which differ only in the orientation of the ~2.4 kb BamHI insert fragment; restriction site maps of pOJ242 and pOJ243 are presented in Figures 3 and 4 of the accompanying drawings.

The BamHI site on plasmid pKC796 resides within a multiple cloning site that itself forms part of the

20 DNA sequence encoding the lacZ α-fragment. Expression of the lacZ α-fragment in an E. coli ΔM15 strain, such as E. coli K12 DH5α, restores the strain's ability to produce a functional β-galactosidase enzyme. Thus, plasmid pKC796 can restore β-galactosidase activity to the E. coli K12 DH5α strain. However, insertion of DNA into a restriction site of the polylinker on plasmid pKC796, as occurs in the construction of plasmids pOJ242 and pOJ243, disrupts the lacZ α-fragment coding sequence and concomitantly destroys

25 the ability of the plasmid pKC796 derivative to complement the ΔM15 mutation. β-galactosidase can hydrolyze X-Gal, which is 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, a colorless compound, to an indigo-colored product and thus allows for a convenient screening method for discriminating between transformants containing starting plasmid pKC796 and those containing a plasmid pKC796 derivative, such as plasmid pOJ242 or pOJ243.

30 Frozen competent DH5α cells (Bethesda Research Laboratories, Inc. (BRL), P.O. Box 6009, Gaithersburg, MD, 20877) were transformed as per manufacturer's instructions. The cells were thawed on ice, 100 µl of cells were removed per transformation, and the unused cells were refrozen in a dry ice-ethanol bath. The 100 µl of cells were added to 1 µl of the ligation reaction which had been diluted 5 fold with water. The cells were incubated on ice for 30 minutes, heat shocked at 42 °C for 2 minutes, and returned to ice for 2-5

35 minutes. One ml of SOC medium was added and the cells were incubated for one hour at 37 °C with shaking. SOC medium is 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 20 mM glucose, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, and 10 mM MgSO₄.

Aliquots of the transformation mixture were plated on L-agar plates containing 100 µg apramycin/ml, 40 µg X-gal/ml, and 40 µg IPTG/ml. IPTG serves to derepress the lac promoter present on plasmid pKC796.

40 The plates were incubated at 37 °C overnight. Colonies that contain a plasmid without an insert, such as E. coli K12 DH5α/pKC796, appear blue on these plates. Colonies that contain a plasmid with an insert, such as E. coli K12 DH5α/pOJ242, are white. Several apramycin-resistant, white colonies were selected and then screened by restriction enzyme analysis of their plasmid DNA. Plasmid DNA was obtained from the E. coli K12 DH5α/pOJ242 and pOJ243 transformants in accordance with the procedure for isolating plasmid DNA.

45 The plasmid pOJ242 and pOJ243 DNAs were used to transform Streptomyces ambofaciens strain 2281 as described in Example 3, below. The publicly available S. ambofaciens strains NRRL 2420 or NRRL 15263 would function equally well.

Example 3

Transformation of Streptomyces

A. List of Solutions

The following solutions are referred to throughout the Examples and are presented here for clarity.

1. P Medium (~100 ml):	
Ingredient	Amount
Sucrose	10.3 g
K ₂ SO ₄	0.025 g
Trace element solution (see #3)	0.2 ml
MgCl ₂ · 6H ₂ O	0.203 g
Water	80 ml
After autoclaving add:	
KH ₂ PO ₄ (0.5%)	1 ml
CaCl ₂ · 2H ₂ O (3.68%)	10 ml
(N-tris-(hydroxymethyl)-methyl-2-aminoethane sulphonic acid), "TES" buffer, 0.25 M, pH = 7.2	10 ml

2. Trace element solution (~1 L):	
Ingredient	Amount
ZnCl ₂	40 mg
FeCl ₃ · 6H ₂ O	200 mg
CuCl ₂ · 2H ₂ O	10 mg
MnCl ₂ · 4H ₂ O	10 mg
Na ₂ B ₄ O ₇ · 10H ₂ O	10 mg
(NH ₄) ₅ Mo ₇ O ₂₄ · 4H ₂ O	10 mg
H ₂ O	1 L

3. Modified R2 Regeneration Medium (~1 L):	
Ingredient	Amount
Sucrose	103 g
K ₂ SO ₄	0.25 g
Trace element solution	2 ml
MgCl ₂ · 6H ₂ O	10.12 g
glucose	10 g
L-asparagine · H ₂ O	2.0 g
casamino acids	0.1 g
Agar	22 g
Water	to 700 ml
The pH is adjusted to pH 7.2 before autoclaving. After autoclaving, add:	
KH ₂ PO ₄ (0.05 g/100 ml)	100 ml
CaCl ₂ (2.22 g/100 ml)	100 ml
TES Buffer (5.73 g/100 ml, pH = 7.2)	100 ml

4. Soft Nutrient Agar (SNA, ~1 L):

Ingredient	Amount
Difco Bacto Nutrient Broth	8 g
Agar	5 g

5. R2YE medium is R2 medium with 20 ml of 25% yeast extract added per liter.

6. Yeast Extract - Malt Extract (YEME, ~1 L):

Ingredient	Amount
Yeast extract	3 g
Peptone	5 g
Malt extract	3 g
Glucose	10 g

7. YEME + 34% Sucrose Liquid Complete Media is YEME with 340 g/L of sucrose.

8. YMX Medium (~1 L):

Ingredient	Amount
Yeast extract	3 g
Malt extract	3 g
Glucose	2 g
Agar	20 g

9. YMX Agar is 0.3% yeast extract, 0.3% malt extract, 0.2% dextrose, and 2.0% agar.

10. Tylosin Fermentation Medium

Ingredient	Amount
Beet Molasses	2%
Corn Meal	1.5%
Fish Meal	0.9%
Corn Gluten	0.9%
Sodium Chloride	0.1%
Ammonium Phosphate (dibasic)	0.04%
Calcium Carbonate	0.2%
Crude Soybean Oil	3%

The pH of this medium was adjusted to 7.1 with 1 N NaOH.

11. AS1 Medium (~1L deionized H ₂ O)	
Ingredient	Amount
Yeast Extract	1 g
L-alanine	0.2 g
L-arginine (free base)	0.2 g
L-asparagine	0.5 g
Soluble Starch	5 g
Sodium Chloride	2.5 g
Sodium Sulfate	10 g
Meer Agar	20 g

12. Spiramycin Fermentation Medium (~1L)	
Ingredient	Amount
Yeast Extract	10 g
KCl	2.5 g
MgSO ₄	0.1 g
KH ₂ PO ₄	10 g
FeCl ₂	0.03 g
ZnCl ₂	0.03 g
MnCl ₂	0.01 g
Ammonium Molybdate	0.005 g

These ingredients were dissolved in 800 ml of water and autoclaved. To this was added sterile potato dextrin (15 g) and glucose (10 g) in 200 ml of water.

13. Modified R2 Soft Agar Overlays	
Ingredient	Amount
Sucrose	51.5 g
MgCl ₂ · H ₂ O	5.06 g
CaCl ₂	1.11 g
0.25M TES (pH 7.2)	50 ml

These ingredients are dissolved in deionized water such that the final volume is 500 ml. The mixture is steamed to melt the agar, decanted into 4 ml aliquots, and autoclaved prior to use.

50 B. Transformation of *S. fradiae*

A culture of *Streptomyces fradiae* was inoculated into 20 ml of trypticase-soya broth (TSB) and incubated in a water-bath incubator at 29 °C at 260 rpm overnight (about 16 hours). The culture was homogenized using a homogenizing vessel (Thomas Scientific, Swedesboro, NJ) and a T-Line laboratory stirrer and then fragmented using a Sonifier Cell Disruptor (Heat Systems Ultrasonics, Inc.) for 7 seconds at 76 Watts. Four ml of the homogenized, fragmented culture were inoculated into 20 ml of TSB (BBL) containing 0.3% weight by volume glycine, and the culture was again incubated overnight at 29 °C. The following morning, the culture was homogenized and recultured as described above. After this third

overnight incubation, the culture was homogenized, collected, and then washed twice with P media.

The cell pellet was resuspended in 15 ml of P media containing 1 mg/ml lysozyme (Calbiochem, La Jolla, CA 92037) and then incubated at room temperature for about one-and-one-half hours to form protoplasts. The protoplasts were gently collected by centrifugation, washed twice with P media, resuspended in 2 ml of P media, and incubated on ice until use. About 1 μ g of plasmid DNA was added to about 50 μ l of 1 mg/ml heparin sulfate (Sigma) and incubated on ice for about 10 minutes. Much less plasmid DNA, about 5-100 nanograms, can be used to transform *Streptomyces fradiae* if prepared from a *S. iradiae* host. The procedure for isolating *Streptomyces* plasmid DNA is described in Hopwood et al., 1985, *Genetic Manipulation of Streptomyces: A Laboratory Manual* (John Innes Foundation, Norwich, England). The DNA/heparin solution was first added to about 200 μ l of protoplasts, and about 0.9 ml of a solution composed of 55% PEG 1000 (Sigma) in P medium was then added to the DNA/protoplast mixture, and the resulting mixture was gently mixed at room temperature.

The mixture was plated in varying aliquots onto R2 plates using 4 ml of soft-R2-agar overlays. After the transformed protoplasts had been plated, the plates were incubated at 29 °C for 24 hours, and then, 4 ml of soft-R2 agar containing 25 μ l of 50 mg/ml thiostrepton (E. R. Squibb, Princeton, NJ 08540) were spread over the protoplasts. Incubation of the plates at 29 °C was continued until regeneration was complete, usually a period of about 7-14 days, to select for the desired *S. fradiae* transformants.

20 C. Transformation of Streptomyces (except for S. fradiae)

One half ml of a fully grown overnight culture of *Streptomyces*, homogenized and sonicated, was used to inoculate 9.5 mls of TSB plus 0.5% glycine. The culture was incubated at 30 °C for 24 hours. After homogenization with a tissue grinder, 0.5 ml of homogenate was used to inoculate 9.5 ml of fresh TSB supplemented with 0.5% glycine. The culture was incubated at 30 °C for 24 hours. The culture was homogenized and transferred to a 50 ml sterile polystyrene centrifuge tube. The cells were pelleted by centrifugation for 10 minutes at 3500 rpm, washed with 10 ml of P medium and resuspended in 10 ml of P medium with 1 mg/ml lysozyme, then incubated at room temperature for 15-30 minutes. Protoplast formation was monitored by examining small samples under a phase-contrast microscope. Protoplasts are spherical.

The protoplasts were centrifuged as before and washed once in P medium. The cells were resuspended in 10 ml of P medium and 150 μ l of protoplasts for each transformation were placed in a 1.5 ml Eppendorf® tube. Up to 10 μ l of DNA in TE buffer were added with gentle mixing. One hundred μ l of 50% polyethylene glycol 1000 in P medium were added immediately. Each transformation mix was split into two tubes of 4 ml of modified R2 top agar and poured onto dried modified R2 plates. The plates were incubated at 30 °C for 24 hours. The plates were then overlaid with modified R2 top agar containing sufficient apramycin for a final plate concentration of 50 μ g/ml. The plates were incubated at 30 °C and transformants appeared 2-3 days later. The transformants were analyzed for the presence of integrated plasmid DNA by Southern analysis in substantial accordance with the procedure in Maniatis et al., 1982, *Molecular Cloning* - (Cold Spring Harbor Laboratory).

Example 4

Assay of Antibiotic Production by Streptomyces

A. Plate-Plug Assay

To determine whether a strain produced antibiotic, *Streptomyces ambofaciens* and *S. fradiae* transformants or parent controls were patched from the R2-agar regeneration plates to AS1 plates and incubated at 30 °C for 2-3 days (5-7 days for *S. fradiae*) until the colonies were 5-10 millimeters in diameter. In order to test the production of isovaleryl spiramycin by *S. ambofaciens* transformed with pOJ242 or pOJ243, the strains were grown on AS1 plates containing A) 50 μ g/ml apramycin; B) 50 μ g/ml apramycin and 100 μ g/ml leucine; C) no additions or D) 100 μ g/ml leucine. The colonies were then plugged with a sterile transfer tube

(Spectrum Medical Industrial, Inc., Los Angeles, CA 90054) and transferred to trypticase soy agar (TSA) plates, which had been previously overlaid with soft-agar nutrient broth (Difco Laboratories, Detroit, MI 48232) containing Micrococcus luteus X160 (ATCC 9341). The plates were incubated at 37° C for 16-24 hours. Micrococcus luteus is sensitive to tylosin and spiramycin and resistant to apramycin. Consequently, M. luteus cannot grow around a plug which contains Streptomyces that are producing tylosin, spiramycin, or isovaleryl spiramycin. A zone of inhibition indicates the presence of antibiotic.

B. Bioautography

10

The agar from an entire plate containing the organism of interest which has been grown for the appropriate time at 30° C was macerated in 10 ml of 1 M Tris-HCl pH 8.0 in a 50 ml polypropylene centrifuge tube. Ten ml of ethyl acetate were added and the mixture was shaken vigorously several times over a period of 1-2 hours at room temperature. The layer were separated in a table-top centrifuge and the top ethyl acetate layer was recovered and evaporated to dryness in a dish. The residue was dissolved in 1 ml of methanol. Approximately 1-20 µl of the methanol extract were applied to a TLC plate and dried. Separation was carried out on a thin-layer chromatography plate (Merck, P.O. Box 2000, Rahway, New Jersey 07065, pre-coated silica gel #60 F-254) next to a tylosin or spiramycin standard. When agar plugs were being assayed, the plugs were left on the plate for a time sufficient for diffusion to occur; then, the plate was subjected to ascending liquid chromatography in 95:5:5 ethylacetate:diethylamine:methanol. The developed chromatograms were dried thoroughly in a fume hood for at least two hours. The chromatograms were then placed face down on Micrococcus luteus X160-seeded TSA plates for ~15 minutes. The chromatograms were removed from the plates, and the plates were incubated at 37° for 16-24 hours. Zones of inhibition were compared with a tylosin or spiramycin standard.

The S. ambofaciens strain containing integrated plasmid pKC796 alone continued to produce spiramycin as demonstrated by isocratic HPLC analysis. Methanol extracts were run on a DuPont Bondapak C18 column (DuPont Co., Instrument Products, Biomedical Division, Newtown, CT 06470) in a mobile phase composed of 80% acetonitrile and 20% 0.1% ammonium bicarbonate, pH = 7. The experimental samples were compared against standards of spiramycin esters. Elution times are given in the following table. The structures of spiramycin I, II and III can be found in Omura and Nakagawa, J. Antibiot. 28:401-433 (1975).

Table XI

Product	Elution Time (Minutes)
With carE	
Isovaleryl spiramycin II	26.5
Isovaleryl spiramycin III	32.0
Butyryl spiramycin II	23.0
Spiramycin standards	
Spiramycin I	15.3
Spiramycin II	16.5
Spiramycin III	19.5

The S. ambofaciens strain integrated with plasmids pOJ242 or pOJ243 produced the novel hybrid antibiotics isovaleryl and butyryl spiramycin. The results are shown below.

In the following table, A stands for 50 µg/ml apramycin and L stands for 100 µg/ml leucine. The results are expressed in terms of percent conversion of spiramycin to isovaleryl and butyryl spiramycin. The "Total Spiramycin + Ester" column is an indication of the overall antibiotic production rate of the transformant. Therefore, a transformant with a high value in that column would be making more isovaleryl and butyryl spiramycin than a transformant with an identical "% conversion" value and a lower "Total Spiramycin + Est r" value. Plasmid pOJ224 is an autonomously replicating vector, unrelated to pKC796, but which comprises the identical carE-comprising fragment as pOJ242 and pOJ243.

Table XII

Growth Conditions and Vector	% Conversion	Total Spiramycin + Ester (μg/sample)
A ⁺ L ⁻		
pKC796	0	2.0
pOJ242	66	1.9
pOJ243	68	1.8
pOJ224	55	0.6
A ⁺ L ⁺		
pKC796	0	1.8
pOJ242	78	1.9
pOJ243	80	1.9
pOJ224	74	0.4
A ⁻ L ⁻		
pKC796	0	2.1
pOJ242	62	1.9
pOJ243	60	2.3
pOJ224	26	0.9
A ⁻ L ⁺		
pKC796	0	3.7
pOJ242	77	2.7
pOJ243	77	3.3
pOJ224	60	0.6

Several conclusions can be drawn from this data. The most important is that a large increase in overall production is obtained with an integrating vector in lieu of an autonomously replicating plasmid. The presence of such a plasmid in a cell diverts many of the cell's resources toward maintaining the plasmid. In turn, the antibiotic production capabilities of the cell may be reduced. The increase in antibiotic production is but one of the many advantages of pKC796 as a vector for maintaining cloned genes. Another observation based on this data is that the carE gene, in either orientation, causes the conversion of large amounts of spiramycin to isovaleryl and butyryl spiramycin. The conversion is augmented by the presence of leucine in the growth medium. Finally, it can be seen that antibiotic selection is not a requirement for maintenance of the carE phenotype with the integrating vector. This represents another significant advantage of pKC796.

Example 5

Construction of Plasmids pSKC50 and pSKC51

A. Isolation of Plasmid pHJL280

Plasmid pHJL280 was isolated from E. coli K12 HB101 on deposit with the NRRL under accession number NRRL B-18043. A restriction site and function map of pHJL280 is presented in Figure 5. The plasmid serves as the source of the tylosin biosynthetic genes tylE, tylD, tylF, tylH and tylJ. These genes are present on an ~6 kb BamHI fragment of pHJL280.

The plasmid was isolated in substantial accordance with Example 1 except that 100 µg/ml ampicillin was used in the medium rather than apramycin.

5 B. Final Construction of Plasmids pSKC50 and pSKC51

Plasmids pSKC50 and pSKC51 are vectors that were used to integrate extra copies of the tylosin biosynthetic genes into the *Streptomyces fradiae* chromosome. The plasmids were constructed in the following manner. About 10 µg (10 µl) of plasmid pKC796 DNA were digested with restriction enzyme
 10 BamHI as per Example 2B. About 20 µg of plasmid pHJL280 were digested with BamHI and the ~6 kb DNA fragment isolated in substantial accordance with Example 2B. The BamHI-digested pKC796 and ~6 kb fragment of pHJL280 were then ligated and transformed into *E. coli* DH5α in substantial accordance with Example 2B. The resulting plasmids were pSKC50 and pSKC51, differing only by the orientation of the ~6 kb BamHI fragment (See Figures 6 and 7). The plasmids were then transformed as described in Example 3,
 15 above, into *S. fradiae* T1405. The samples were then assayed for tylosin production in substantial accordance with Example 4, above.

The results with experiments utilizing the *S. fradiae* production strain were as follows. The results are expressed as percent of tylosin produced as compared to the control T1405 production strain (with no vector integrated).

20 Table XII

Strain	Tylosin Produced	
	% of Control	
	Experiment 1	Experiment 2
T1405	100	100
T1405/pKC796	not done	98
25 T1405/pSKC50 or pSKC51	133	136

30 The results indicate that integrating extra copies of the tylosin biosynthetic genes increases tylosin production by a substantial amount.

35 Example 6

40 Transformation of tyl^r Mutant Strains GS15 and GS16 with Plasmid pKC796, pSKC50 and pSKC51

Streptomyces fradiae strains GS15 and GS16 are grown, protoplasted and transformed with pSKC50 and pSKC51 as described in Example 3. Apramycin resistant transformants containing pSKC50 or pSKC51 are grown in TS broth plus 50 µg/ml of apramycin for about 48 hours or until the cultures reach stationary phase. One-half ml of each culture is inoculated into 7 ml of tylosin fermentation medium (Example 3) and the culture is incubated at 29 °C for seven days with rapid agitation. Five ml of methanol are added to each culture. After mixing by hand shaking, the methanol diluted fermentation cultures are filtered through
 50 Whatman #1 paper. The filtrates are analyzed for the presence of tylosin, macrocin and demethylmacrocin by thin layer chromatography (Baltz and Seno, *Antimicrob. Agents Chemother.* 20:214-225 (1981)) and HPLC (Kennedy, J. *Chrom.* 281:288-292 (1983)). The results are compared to those from concurrently run control cultures consisting of GS15 or GS16 without pSKC50 or pSKC51.

55 Claims

1. A method of transforming an actinomycete, which comprises the step of introducing into said

actinomycete a plasmid comprising a DNA sequence, such DNA sequence containing site-specific integrating functions of phage ØC31 subject to the limitation that the plasmid not be capable of directing plaque formation.

2. The method of Claim 1; wherein said DNA sequence comprising the site-specific integrating functions of phage ØC31 is

10 GAC GTC CCG AAG GCG TGG CGC GGC TTC CCC GTG CCG GAG CAA
 TCG CCC TGG GTG GGT TAC ACG ACG CCC CTC TAT GGC CCG TAC
 TGA CGG ACA CAC CGA AGC CCC GGC GGC AAC CCT CAG CGG ATG
 15 CCC CGG GGC TTC ACG TTT TCC CAG GTC AGA AGC GGT TTT CGG
 GAG TAG TGC CCC AAC TGG GGT AAC CTT TGA GTT CTC TCA GTT
 GGG GGC GTA GGG TCG CCG ACA TGA CAC AAG GGG TTG TGA CCG
 GGG TGG ACA CGT ACG CGG GTG CTT ACG ACC GTC AGT CGC GCG
 AGC GCG AGA ATT CGA GCG CAG CAA GCC CAG CGA CAC AGC GTA
 20 GCG CCA ACG AAG ACA AGG CGG CCG ACC TTC AGC GCG AAG TCG
 AGC GCG ACG GGG GCC GGT TCA GGT TCG TCG GGC ATT TCA GCG
 AAG CGC CGG GCA CGT CGG CGT TCG GGA CGG CGG AGC GCC CGG
 AGT TCG AAC GCA TCC TGA ACG AAT GCC GCG CCG GGC GGC TCA
 25 ACA TGA TCA TTG TCT ATG ACG TGT CGC GCT TCT CGC GCC TGA
 AGG TCA TGG ACG CGA TTC CGA TTG TCT CGG AAT TGC TCG CCC
 TGG GCG TGA CGA TTG TTT CCA CTC AGG AAG GCG TCT TCC GGC
 AGG GAA ACG TCA TGG ACC TGA TTC ACC TGA TTA TGC GGC TCG
 30 ACG CGT CGC ACA AAG AAT CTT CGC TGA AGT CGG CGA AGA TTC
 TCG ACA CGA AGA ACC TTC AGC GCG AAT TGG GCG GGT ACG TCG
 GCG GGA AGG CGC CTT ACG GCT TCG AGC TTG TTT CGG AGA CGA
 35 AGG AGA TCA CGC GCA ACG GCC GAA TGG TCA ATG TCG TCA TCA

40

45

50

55

ACA AGC TTG CGC ACT CGA CCA CTC CCC TTA CCG GAC CCT TCG
 AGT TCG AGC CCG ACG TAA TCC GGT GGT GGT GGC GTG AGA TCA
 5 AGA CGC ACA AAC ACC TTC CCT TCA AGC CGG GCA GTC AAG CCG
 CCA TTC ACC CGG GCA GCA TCA CGG GGC TTT GTA AGC GCA TGG
 ACG CTG ACG CCG TGC CGA CCC GGG GCG AGA CGA TTG GGA AGA
 AGA CCG CTT CAA GCG CCT GGG ACC CGG CAA CCG TTA TGC GAA
 10 TCC TTC GGG ACC CGC GTA TTG CGG GCT TCG CCG CTG AGG TGA
 TCT ACA AGA AGA AGC CGG ACG GCA CGC CGA CCA CGA AGA TTG
 AGG GTT ACC GCA TTC AGC GCG ACC CGA TCA CGC TCC GGC CGG
 15 TCG AGC TTG ATT GCG GAC CGA TCA TCG AGC CCG CTG AGT GGT
 ATG AGC TTC AGG CGT GGT TGG ACG GCA GGG GGC GCG GCA AGG
 GGC TTT CCC GGG GGC AAG CCA TTC TGT CCG CCA TGG ACA AGC
 TGT ACT GCG AGT GTG GCG CCG TCA TGA CTT CGA AGC GCG GGG
 20 AAG AAT CGA TCA AGG ACT CTT ACC GCT GCC GTC GCC GGA AGG
 TGG TCG ACC CGT CCG CAC CTG GGC AGC ACG AAG GCA CGT GCA
 ACG TCA GCA TGG CGG CAC TCG ACA AGT TCG TTG CGG AAC GCA
 25 TCT TCA ACA AGA TCA GGC ACG CCG AAG GCG ACG AAG AGA CGT
 TGG CGC TTC TGT GGG AAG CCG CCC GAC GCT TCG GCA AGC TCA
 CTG AGG CGC CTG AGA AGA GCG GCG AAC GGG CGA ACC TTG TTG
 30 CGG AGC GCG CCG ACG CCC TGA ACG CCC TTG AAG AGC TGT ACG
 AAG ACC GCG CGG CAG GCG CGT ACG ACG GAC CCG TTG GCA GGA
 AGC ACT TCC GGA AGC AAC AGG CAG CGC TGA CGC TCC GGC AGC
 AAG GGG CGG AAG AGC GGC TTG CCG AAC TTG AAG CCG CCG AAG
 35 CCC CGA AGC TTC CCC TTG ACC AAT GGT TCC CCG AAG ACG CCG
 ACG CTG ACC CGA CCG GCC CTA AGT CGT GGT GGG GGC GCG CGT
 CAG TAG ACG ACA AGC GCG TGT TCG TCG GGC TCT TCG TAG ACA
 40 AGA TCG TTG TCA CGA AGT CGA CTA CGG GCA GGG GGC AGG GAA
 CGC CCA TCG AGA AGC GCG CTT CGA TCA CGT GGG CGA AGC CGC
 CGA CCG ACG ACG ACG AAG ACG ACG CCC AGG ACG GCA CGG AAG
 45 ACG TAG CGG CGT AGC GAG ACA CCC GGG AAG CCT

wherein A is a deoxyadenyl residue, G is a deoxyguanyl residue, C is a deoxycytidyl residue, and T is a thymidyl residue.

3. A plasmid selected from the group consisting of pKC796, pOJ242, pOJ243, pSKC50, and pSKC51.
4. Plasmid pKC796.
5. Plasmid pOJ242.
6. Plasmid pOJ243.
7. Plasmid pSKC50.
8. Plasmid pSKC51.
9. A method for producing hybrid antibiotics, said method comprising 1) transforming a microorganism with a plasmid vector comprising a DNA sequence which contains a site specific integrating functions of ϕ C31, said vector also comprising an antibiotic biosynthetic gene that codes for an enzyme or other gene

product not previously expressed in said microorganism and that converts said antibiotic to a hybrid antibiotic not previously produced by said microorganism and 2) culturing said microorganism transformed with said vector under conditions suitable for producing the hybrid antibiotic.

10. The method of Claim 9, wherein said DNA sequence comprising the site-specific integrating
5 functions of phage ØC31 is

10 GAC GTC CCG AAG GCG TGG CGC GGC TTC CCC GTG CCG GAG CAA
TCG CCC TGG GTG GGT TAC ACG ACG CCC CTC TAT GGC CCG TAC
TGA CGG ACA CAC CGA AGC CCC GGC GGC AAC CCT CAG CGG ATG
15 CCC CGG GGC TTC ACG TTT TCC CAG GTC AGA AGC GGT TTT CGG
GAG TAG TGC CCC AAC TGG GGT AAC CTT TGA GTT CTC TCA GTT
GGG GGC GTA GGG TCG CCG ACA TGA CAC AAG GGG TTG TGA CCG
20
25
30
35
40
45
50
55

5 GGG TGG ACA CGT ACG CGG GTG CTT ACG ACC GTC AGT CGC GCG
 AGC GCG AGA ATT CGA GCG CAG CAA GCC CAG CGA CAC AGC GTA
 GCG CCA ACG AAG ACA AGG CGG CCG ACC TTC AGC GCG AAG TCG
 AGC GCG ACG GGG GCC GGT TCA GGT TCG TCG GGC ATT TCA GCG
 AAG CGC CGG GCA CGT CGG CGT TCG GGA CGG CGG AGC GCC CGG
 10 AGT TCG AAC GCA TCC TGA ACG AAT GCC GCG CCG GGC GGC TCA
 ACA TGA TCA TTG TCT ATG ACG TGT CGC GCT TCT CGC GCC TGA
 AGG TCA TGG ACG CGA TTC CGA TTG TCT CGG AAT TGC TCG CCC
 TGG GCG TGA CGA TTG TTT CCA CTC AGG AAG GCG TCT TCC GGC
 15 AGG GAA ACG TCA TGG ACC TGA TTC ACC TGA TTA TGC GGC TCG
 ACG CGT CGC ACA AAG AAT CTT CGC TGA AGT CGG CGA AGA TTC
 TCG ACA CGA AGA ACC TTC AGC GCG AAT TGG GCG GGT ACG TCG
 20 GCG GGA AGG CGC CTT ACG GCT TCG AGC TTG TTT CGG AGA CGA
 AGG AGA TCA CGC GCA ACG GCC GAA TGG TCA ATG TCG TCA TCA
 ACA AGC TTG CGC ACT CGA CCA CTC CCC TTA CCG GAC CCT TCG
 AGT TCG AGC CCG ACG TAA TCC GGT GGT GGT GGC GTG AGA TCA
 25 AGA CGC ACA AAC ACC TTC CCT TCA AGC CGG GCA GTC AAG CCG
 CCA TTC ACC CGG GCA GCA TCA CGG GGC TTT GTA AGC GCA TGG
 ACG CTG ACG CCG TGC CGA CCC GGG GCG AGA CGA TTG GGA AGA
 30 AGA CCG CTT CAA GCG CCT GGG ACC CGG CAA CCG TTA TGC GAA
 TCC TTC GGG ACC CGC GTA TTG CGG GCT TCG CCG CTG AGG TGA
 TCT ACA AGA AGA AGC CGG ACG GCA CGC CGA CCA CGA AGA TTG
 35 AGG GTT ACC GCA TTC AGC GCG ACC CGA TCA CGC TCC GGC CGG
 TCG AGC TTG ATT GCG GAC CGA TCA TCG AGC CCG CTG AGT GGT
 ATG AGC TTC AGG CGT GGT TGG ACG GCA GGG GGC GCG GCA AGG
 GGC TTT CCC GGG GGC AAG CCA TTC TGT CCG CCA TGG ACA AGC
 40 TGT ACT GCG AGT GTG GCG CCG TCA TGA CTT CGA AGC GCG GGG
 AAG AAT CGA TCA AGG ACT CTT ACC GCT GCC GTC GCC GGA AGG
 TGG TCG ACC CGT CCG CAC CTG GGC AGC ACG AAG GCA CGT GCA
 45 ACG TCA GCA TGG CGG CAC TCG ACA AGT TCG TTG CGG AAC GCA
 TCT TCA ACA AGA TCA GGC ACG CCG AAG GCG ACG AAG AGA CGT

50

55

5 TGG CGC TTC TGT GGG AAG CCG CCC GAC GCT TCG GCA AGC TCA
 CTG AGG CGC CTG AGA AGA GCG GCG AAC GGG CGA ACC TTG TTG
 CGG AGC GCG CCG ACG CCC TGA ACG CCC TTG AAG AGC TGT ACG
 AAG ACC GCG CGG CAG GCG CGT ACG ACG GAC CCG TTG GCA GGA
 AGC ACT TCC GGA AGC AAC AGG CAG CGC TGA CGC TCC GGC AGC
 AAG GGG CGG AAG AGC GGC TTG CCG AAC TTG AAG CCG CCG AAG
 10 CCC CGA AGC TTC CCC TTG ACC AAT GGT TCC CCG AAG ACG CCG
 ACG CTG ACC CGA CCG GCC CTA AGT CGT GGT GGG GGC GCG CGT
 CAG TAG ACG ACA AGC GCG TGT TCG TCG GGC TCT TCG TAG ACA
 15 AGA TCG TTG TCA CGA AGT CGA CTA CGG GCA GGG GGC AGG GAA
 CGC CCA TCG AGA AGC GCG CTT CGA TCA CGT GGG CGA AGC CGC
 CGA CCG ACG ACG ACG AAG ACG ACG CCC AGG ACG GCA CGG AAG
 20 ACG TAG CGG CGT AGC GAG ACA CCC GGG AAG CCT

wherein A is a deoxyadenyl residue, G is a deoxyguanyl residue, C is a deoxycytidyl residue, and T is a thymidyl residue.

11. The method of Claim 9 wherein said hybrid antibiotic is isovaleryl spiramycin.

25 12. A method for increasing the antibiotic-producing or antibiotic precursor-producing ability of an antibiotic-producing or antibiotic precursor-producing microorganism, said method comprising
 1) transforming a microorganism that produces an antibiotic or an antibiotic precursor by means of an antibiotic biosynthetic pathway with an integrating vector comprising a DNA sequence that comprises the site-specific integrating functions of phage ØC31, said vector also comprising an antibiotic bio synthetic
 30 gene that codes for an enzyme or other gene product that is rate-limiting in said biosynthetic pathway; and
 2) culturing said microorganism transformed with said vector under conditions suitable for cell growth, expression of said antibiotic biosynthetic gene, and production of antibiotic or an antibiotic precursor, subject to the limitation that said antibiotic biosynthetic gene selected in step (1) provides for an increase in the antibiotic-producing or antibiotic precursor-producing ability of said microorganism.

35 13. The method of Claim 12, wherein said DNA sequence comprising the site-specific integrating functions of phage ØC31 is

40

45

50

55

EP 0 403 173 A2

5 GAC GTC CCG AAG GCG TGG CGC GGC TTC CCC GTG CCG GAG CAA
 TCG CCC TGG GTG GGT TAC ACG ACG CCC CTC TAT GGC CCG TAC
 TGA CGG ACA CAC CGA AGC CCC GGC GGC AAC CCT CAG CGG ATG
 10 CCC CGG GGC TTC ACG TTT TCC CAG GTC AGA AGC GGT TTT CGG
 GAG TAG TGC CCC AAC TGG GGT AAC CTT TGA GTT CTC TCA GTT
 GGG GGC GTA GGG TCG CCG ACA TGA CAC AAG GGG TTG TGA CCG
 15 GGG TGG ACA CGT ACG CGG GTG CTT ACG ACC GTC AGT CGC GCG
 AGC GCG AGA ATT CGA GCG CAG CAA GCC CAG CGA CAC AGC GTA
 GCG CCA ACG AAG ACA AGG CGG CCG ACC TTC AGC GCG AAG TCG
 AGC GCG ACG GGG GCC GGT TCA GGT TCG TCG GGC ATT TCA GCG
 20 AAG CGC CGG GCA CGT CGG CGT TCG GGA CGG CGG AGC GCC CGG
 AGT TCG AAC GCA TCC TGA ACG AAT GCC GCG CCG GGC GGC TCA
 ACA TGA TCA TTG TCT ATG ACG TGT CGC GCT TCT CGC GCC TGA
 AGG TCA TGG ACG CGA TTC CGA TTG TCT CGG AAT TGC TCG CCC
 TGG GCG TGA CGA TTG TTT CCA CTC AGG AAG GCG TCT TCC GGC

25

30

35

40

45

50

55

5 AGG GAA ACG TCA TGG ACC TGA TTC ACC TGA TTA TGC GGC TCG
 ACG CGT CGC ACA AAG AAT CTT CGC TGA AGT CGG CGA AGA TTC
 TCG ACA CGA AGA ACC TTC AGC GCG AAT TGG GCG GGT ACG TCG
 GCG GGA AGG CGC CTT ACG GCT TCG AGC TTG TTT CGG AGA CGA
 AGG AGA TCA CGC GCA ACG GCC GAA TGG TCA ATG TCG TCA TCA
 10 ACA AGC TTG CGC ACT CGA CCA CTC CCC TTA CCG GAC CCT TCG
 AGT TCG AGC CCG ACG TAA TCC GGT GGT GGT GGC GTG AGA TCA
 AGA CGC ACA AAC ACC TTC CCT TCA AGC CGG GCA GTC AAG CCG
 CCA TTC ACC CGG GCA GCA TCA CGG GGC TTT GTA AGC GCA TGG
 15 ACG CTG ACG CCG TGC CGA CCC GGG GCG AGA CGA TTG GGA AGA
 AGA CCG CTT CAA GCG CCT GGG ACC CGG CAA CCG TTA TGC GAA
 TCC TTC GGG ACC CGC GTA TTG CGG GCT TCG CCG CTG AGG TGA
 20 TCT ACA AGA AGA AGC CGG ACG GCA CGC CGA CCA CGA AGA TTG
 AGG GTT ACC GCA TTC AGC GCG ACC CGA TCA CGC TCC GGC CGG
 TCG AGC TTG ATT GCG GAC CGA TCA TCG AGC CCG CTG AGT GGT
 ATG AGC TTC AGG CGT GGT TGG ACG GCA GGG GGC GCG GCA AGG
 25 GGC TTT CCC GGG GGC AAG CCA TTC TGT CCG CCA TGG ACA AGC
 TGT ACT GCG AGT GTG GCG CCG TCA TGA CTT CGA AGC GCG GGG
 AAG AAT CGA TCA AGG ACT CTT ACC GCT GCC GTC GCC GGA AGG
 30 TGG TCG ACC CGT CCG CAC CTG GGC AGC ACG AAG GCA CGT GCA
 ACG TCA GCA TGG CGG CAC TCG ACA AGT TCG TTG CGG AAC GCA
 TCT TCA ACA AGA TCA GGC ACG CCG AAG GCG ACG AAG AGA CGT
 35 TGG CGC TTC TGT GGG AAG CCG CCC GAC GCT TCG GCA AGC TCA
 CTG AGG CGC CTG AGA AGA GCG GCG AAC GGG CGA ACC TTG TTG
 CGG AGC GCG CCG ACG CCC TGA ACG CCC TTG AAG AGC TGT ACG
 AAG ACC GCG CGG CAG GCG CGT ACG ACG GAC CCG TTG GCA GGA
 40 AGC ACT TCC GGA AGC AAC AGG CAG CGC TGA CGC TCC GGC AGC
 AAG GGG CGG AAG AGC GGC TTG CCG AAC TTG AAG CCG CCG AAG
 CCC CGA AGC TTC CCC TTG ACC AAT GGT TCC CCG AAG ACG CCG
 45 ACG CTG ACC CGA CCG GCC CTA AGT CGT GGT GGG GGC GCG CGT
 CAG TAG ACG ACA AGC GCG TGT TCG TCG GGC TCT TCG TAG ACA
 50
 AGA TCG TTG TCA CGA AGT CGA CTA CGG GCA GGG GGC AGG GAA
 CGC CCA TCG AGA AGC GCG CTT CGA TCA CGT GGG CGA AGC CGC
 CGA CCG ACG ACG ACG AAG ACG ACG CCC AGG ACG GCA CGG AAG
 55 ACG TAG CGG CGT AGC GAG ACA CCC GGG AAG CCT

wherein A is a deoxyadenyl residue, G is a deoxyguanyl residue, C is a deoxycytidyl residue, and T is a

thymidyl residue.

14. An actinomycete transformed with a plasmid comprising the site-specific integrating functions of phage ØC31 subject to the limitation that the plasmid not be capable of directing plaque formation.

15. The actinomycete of Claim 14 transformed with a plasmid selected from the group consisting of pKC796, pOJ242, pOJ243, pSKC50, and pSKC51.

Claims for the following Contracting States: ES, GR

1. A process of transforming an actinomycete, which comprises the step of introducing into said actinomycete a plasmid comprising a DNA sequence, such DNA sequence containing site-specific integrating functions of phage ØC31 subject to the limitation that the plasmid not be capable of directing plaque formation.

2. A process according to Claim 1 for transforming Streptomyces, Nocardia, or Saccharopolyspora.

3. A process according to Claim 1 for transforming Streptomyces.

4. A process according to Claim 3 for transforming Streptomyces fradiae, S. griseofuscus, S. thermotolerans, or S. ambofaciens.

5. A process according to Claim 4 for transforming Streptomyces fradiae.

6. A process according to Claim 4 for transforming Streptomyces ambofaciens.

7. A process according to Claim 1 wherein said plasmid is pKC796, pOJ242, pOJ243, pSKC50, and pSKC51.

8. A process according to Claim 7 wherein said plasmid is pOJ242.

9. A process according to Claim 7 wherein said plasmid is pOJ243.

10. A process according to Claim 7 wherein said plasmid is pSKC50.

11. A process according to Claim 7 wherein said plasmid is pSKC51.

FIG. 1
Restriction Site and Function
Map of Plasmid pKC796
(~6.7 kb)




FIG.2
Restriction Site and Function
Map of Plasmid pOJ171
(~45 kb)




FIG.3
Restriction Site and Function
Map of Plasmid pOJ242
(~9.1 kb)




FIG.4
Restriction Site and Function
Map of Plasmid pOJ243
(~9.1 kb)




FIG.5
Restriction Site and Function
Map of Plasmid pHJL280
(~27 kb)




FIG.6
Restriction Site and Function
Map of Plasmid pSKC50
(~12.6 kb)





FIG. 7
Restriction Site and Function
Map of Plasmid pSKC51
(~12.6 kb)



19



Europäisches Patentamt
European Patent Office
Office européen des brevets



11 Publication number:

0 403 173 A3

12

EUROPEAN PATENT APPLICATION

21 Application number: 90306260.2

22 Date of filing: 08.06.90

51 Int. Cl.⁵: **C12N 15/76, C12N 15/90,
C12P 19/62, //(C12N15/76,
C12R1:465)**

30 Priority: 12.06.89 US 364959

43 Date of publication of application:
19.12.90 Bulletin 90/51

84 Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI NL SE

98 Date of deferred publication of the search report:
11.09.91 Bulletin 91/37

71 Applicant: **ELI LILLY AND COMPANY**
Lilly Corporate Center
Indianapolis Indiana 46285(US)

72 Inventor: **Cox, Karen Leigh**
Box 204 Painted Hills
Martinsville, Indiana 46151(US)
Inventor: **Richardson, Mark Alan**
4906 North Central Avenue
Indianapolis, Indiana 46205(US)
Inventor: **Kuhstoss, Stuart Allen**
5339 North Park Avenue
Indianapolis, Indiana 46220(US)
Inventor: **Schoner, Brigitte Elisabeth**
R.R. 2, Box 30 F
Monrovia, Indiana 4657(US)
Inventor: **Rao, Ramachandra Nagaraja**
9110 Misty Lake Circle
Indianapolis, Indiana 46260(US)
Inventor: **Seno, Eugene Thomas**
5109 East 72nd Court
Indianapolis, Indiana 46250(US)

74 Representative: **Hudson, Christopher Mark et al**
Erl Wood Manor
Windlesham Surrey GU20 6PH(GB)

54 Novel use of the site-specific integrating function of phage OC31.

57 The present invention provides a method for transforming an actinomycete with an integrating vector which has the advantages of high transformation rates into a broad host range, site-specific integration, and stable maintenance without antibiotic selection. Also provided are methods for the increased production of antibiotics and for the production of hybrid antibiotics.

EP 0 403 173 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 30 6260

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D, Y	JOURNAL OF BACTERIOLOGY vol. 171, no. 1, January 1989, BALTIMORE US pages 16 - 23; S. Kuhstoss et al.: "Site-specific integration in Streptomyces ambofaciens: localization of integration functions in S. ambofaciens plasmid pSAM2" * abstract; figure 6 * * page 20, line 3 - page 22, line 18 * ---	1, 14	C12N15/76 C12N15/90 C12P19/62// (C12N15/76, C12R1:465)
Y	GENE. vol. 34, no. 2/3, 1985, AMSTERDAM NL pages 283 - 292; I. Rosario Rodicio et al.: "New derivatives of the Streptomyces temperate phage phiC31 useful for the cloning and functional analysis of streptomyces DNA" * the whole document * ---	1, 14	
A	EP-A-288200 (ELI LILLY AND COMPANY) * the whole document * ---	3, 9-12	
A	BIOTECHNOLOGY vol. 4, September 1986, NEW YORK US pages 786 - 789; J.T Fayerman: "New developments in gene cloning in antibiotic producing microorganisms" * the whole document * -----	1, 9, 12, 14	TECHNICAL FIELDS SEARCHED (Int. Cl.5) C12N15
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 16 JULY 1991	Examiner GURDJIAN D.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons ----- & : member of the same patent family, corresponding document			

EPO FORM 1501 (01.82) (P0401)